{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:57:20Z","timestamp":1774022240908,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Prognosis of relapsed leukemia patients after second allogeneic hematopoietic stem cell transplantation (HSCT2) is historically considered very poor. We report the outcome of 18 pediatric patients after failure of HSCT2. The 2-year overall survival was 26% (95% confidence interval [CI], 6-47). The lymphoid malignancies were associated with better survival (40% [95% CI, 12-68]) than myeloid malignancies (0%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002), together with time to relapse after the HSCT2 (\u22655\u2009mo: 44% [95% CI, 12-76] vs. 0% for patients who relapsed within 5\u2009mo from HSCT2, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.005), other factors such as sex, donor type, conditioning regimen, and graft versus host disease prophylaxis did not have statistical significance. When the multivariate analysis was carried out, 2 independent protective factors were identified: the lymphoid malignancies and the graft versus host disease 0 to I after HSCT2. When we look at the treatments, patients receiving blinatumomab after relapse got benefit in terms of overall survival and, more importantly, with a long-term control of acute lymphoblastic leukemia.<\/jats:p>","DOI":"10.1097\/mph.0000000000001507","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T11:00:41Z","timestamp":1556794841000},"page":"e506-e509","source":"Crossref","is-referenced-by-count":3,"title":["Outcome of Relapsed Pediatric Patients After Second Allogeneic Hematopoetic Stem Cell Transplantation: A Retrospective Study From a Single Institution"],"prefix":"10.1097","volume":"41","author":[{"given":"Massimo","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Pessolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena E.","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11899-018-0476-4","article-title":"Hematopoietic stem cell transplantation in the era of engineered cell therapy","volume":"13","author":"Appelbaum","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.hemonc.2017.05.021","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia: a review","volume":"10","author":"Kassim","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.bbmt.2018.12.007","article-title":"Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era","volume":"25","author":"Xue","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","article-title":"Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia","volume":"25","author":"Lund","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbmt.2018.08.012","article-title":"Kinetics and risk factors of relapse after allogeneic stem cell transplantation in children with leukemia: a long-term follow-up single-center study","volume":"25","author":"Molina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP Study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-018-0203-8","article-title":"Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia","volume":"54","author":"Craddock","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exphem.2018.03.002","article-title":"Analysis of relapse after transplantation in acute leukemia: a comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions","volume":"62","author":"Ort\u00ed","year":"2018","journal-title":"Exp Hematol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MOP.0000000000000293","article-title":"Therapies on the horizon for childhood acute lymphoblastic leukemia","volume":"28","author":"Carroll","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2013.08.016","article-title":"Proceedings from the National Cancer Institute\u2019s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction","volume":"19","author":"Wayne","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bbmt.2013.08.010","article-title":"Proceedings from the National Cancer Institute\u2019s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part I. Biology of relapse after transplantation","volume":"19","author":"Gress","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:20:04Z","timestamp":1695010804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001507","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}